Antibodies User Survey

Findings show researchers value quality over low price

May 1, 2012
Christi Bird

Used in a wide variety of technologies and applications, research antibodies are major money-makers for life science tool companies, generating 2011 revenues of $1.6 billion globally. Antibodies are critical to many widely-used technologies, including western blots, enzyme-linked immunosorbent assays (ELISA), immunohistochemistry (IHC), flow cytometry, and chromatin immunoprecipitation (ChIP), to name a few. Over 300 suppliers worldwide offer over half a million different types of research antibodies. Yet, even with a huge competitor base and a flood of antibodies available, competition remains fierce, with new suppliers entering the market every year, which is good news for researchers looking for the highest quality products. Scientists continue to expand the applications enabled by antibody-based technologies, demanding the development of antibodies for new targets of interest and rarely-studied species.

The Scientist and Frost & Sullivan recently conducted an online survey in order to better understand the marketplace for research antibodies. The survey captures the purchasing, budget, application, and technology trends of research antibody use. Additionally, the survey determines customer ratings of suppliers, supplier usage, unmet needs, and challenges. A total of 1,155 subscribers of The Scientist qualified for the survey based on their purchasing roles for research antibodies, current use of antibodies, or planned use of antibodies within the next 12 months. These respondents represent academic institutions, federal and state government laboratories, pharmaceutical, biotechnology and diagnostic companies, hospital and clinical laboratories, and private non-profit organizations globally. The figures below present the demographics of this survey.

Survey participants reveal that 88 percent of their laboratories currently use research antibodies, while 12 percent plan to use research antibodies in the next 12 months. Current users of research antibodies were asked to indicate the types of antibodies they utilize in their laboratory research from a list of over 25 categories. Antibodies for studying cell signaling/signal transduction and membrane receptors are the most popularly employed among current users, with transcription factors and intracellular proteins coming in close behind.

Antibodies remain critical components in a wide range of research technologies. By far the most commonly used application for research antibodies is western blot, as over three-quarters of respondents employed this technique in 2011 and plan to continue using it in 2012. Beyond western blot, fluorescence microscopy and immunofluorescence were also popular, and immunoprecipitation is expected to be adopted at the fastest rate in 2012. However, microarrays and electron microscopy are two technologies that did not crack the top ten in current usage. Researchers also provided information on which antibody suppliers they used within the past 12 months, and were asked to rate their overall antibody purchasing experiences with these companies.  The three most popularly used suppliers of research antibodies were Sigma-Aldrich, Santa Cruz Biotechnology, and Abcam. Interestingly, less-used suppliers such as Cell Signaling Technology, BioLegend, and eBioscience were the three most highly-rated companies. Specifically, Abcam falls within the top 15 of customer-rated antibody suppliers, but Santa Cruz Biotechnology and Sigma-Aldrich receive much lower positive ratings (12 percent and 20 percent of customers, respectively, assign them an excellent rating)..

For more information contact: Britni MyersCorporate Communications for Frost & Sullivan, North America.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.